The Zhitong Finance App learned that while Danish pharmaceutical giant Novo Nordisk (NVO.US) is struggling to maintain its leading position in the obesity market, radical hedge fund Parvus Asset Management has increased its shares, and the stock price has risen to the highest level in more than two months. As of press time, the stock was up 2.5% in the premarket. At one point, the company's stock price rose 3.5% in the Copenhagen market. According to the Financial Times, London-based Parvus intends to influence the appointment of Novo Nordisk's new CEO.

The Zhitong Finance App learned that while Danish pharmaceutical giant Novo Nordisk (NVO.US) is struggling to maintain its leading position in the obesity market, radical hedge fund Parvus Asset Management has increased its shares, and the stock price has risen to the highest level in more than two months. As of press time, the stock was up 2.5% in the premarket. At one point, the company's stock price rose 3.5% in the Copenhagen market. According to the Financial Times, London-based Parvus intends to influence the appointment of Novo Nordisk's new CEO.